Phase 1 study of the effects of nitric oxide inhibition with L-NMMA in patients with liver cirrhosis and healthy controls. It is hypothesized that nitric oxide availability is increased in liver cirrhosis.
In a randomized, placebo controlled design the acute effects of Ng-monomethyl-L-arginine are studied on: * renal hemodynamics (GFR and RPF) * blood pressure and heart rate * lithium clearance * plasma levels of vasoactive hormones
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
SINGLE
Enrollment
30
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.